Tag: Continuous Active Leaning

1
In re Valsartan, Losartan, and Irbesartan Prods. Liab. Litig. (D.N.J. Dec. 2, 2020)

In re Valsartan, Losartan, and Irbesartan Prods. Liab. Litig. (D.N.J. Dec. 2, 2020)

Key Insight: Defendants violated the Court ordered ESI protocol when it unilaterally adopted a CAL platform without input from Plaintiffs. Defendants failed to timely disclose their intentions to use TAR and collaborate in good faith with Plaintiffs on the TAR platform to be used prior to implementation. Due to the cost and time required for a manual review, the Court permitted Defendants to do a TAR review of its non-responsive documents using the protocol previously negotiated but not finalized by the parties.

Nature of Case: Products Liability

Electronic Data Involved: Electronic Documents Generally

Case Summary

Copyright © 2022, K&L Gates LLP. All Rights Reserved.